Neu­ro­crine CEO Kevin Gor­man to re­tire af­ter 32-year run; Blue­bird picks up fifth CFO in three years

Af­ter more than three decades at Neu­ro­crine, CEO Kevin Gor­man will re­tire lat­er this year, hand­ing the reins of the $13 bil­lion neu­ro­science drug­mak­er over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.